Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2/3 1Phase 2 1

Status

Terminated 1Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4CNS 1

Conditions

Melanoma 32Carcinoma, Non-Small-Cell Lung 22Carcinoma, Renal Cell 19Neoplasm Metastasis 13Carcinoma, Hepatocellular 10Brain Neoplasms 8Lung Neoplasms 7Skin Neoplasms 6Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Prostatic Neoplasms 5Pancreatic Neoplasms 5Kidney Neoplasms 5Clear-cell metastatic renal cell carcinoma 5Carcinoma, Transitional Cell 5Uveal Melanoma 4Sarcoma 4Ovarian Neoplasms 4Myelodysplastic Syndromes 4Multiple Myeloma 4Glioblastoma 4Carcinoma, Basal Cell 4Carcinoma 4Urinary Bladder Neoplasms 3Urethral Neoplasms 3Recurrence 3Mesothelioma 3Liver Neoplasms 3Leukemia, Myeloid, Acute 3Histiocytoma, Malignant Fibrous 3

Interventions

Nivolumab 5pembrolizumab 4Ipilimumab 4Cyclophosphamide 4Specimen Handling 3tebentafusp 2fludarabine phosphate 2fludarabine 2Radiosurgery 2Magnetic Resonance Spectroscopy 2Interleukin-2 2Blood Specimen Collection 2trametinib 1ruxolitinib 1omipalisib 1olaparib 1binimetinib 1belinostat 1avelumab 1Vorinostat 1Valproic Acid 1Tape Recording 1Sunitinib 1Spinal Puncture 1Practice Guidelines as Topic 1Pemetrexed 1Methods 1LY2940680 1Iodized Oil 1Interleukin-13 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Uveal Melanoma × Ipilimumab × 90 days × Clear all
NCT05341349 2026-04-23

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

Emory University

Phase 1 Terminated
1 enrolled
CNSDermatologic

Uveal Melanoma, Brain Neoplasms, Melanoma

NCT06581406 2026-04-02

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Replimune, Inc.

Phase 2/3 Recruiting
280 enrolled
Dermatologic

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT07501117 2026-03-30

Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma

Herlev Hospital

Phase 1 Not yet recruiting
15 enrolled
Dermatologic

Uveal Melanoma

NCT03070392 2026-03-17

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Immunocore Ltd

Phase 2 Completed
378 enrolled 15 charts 1 FDA
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡